Search research articles
Contact Us
Filters
Showing results (161-170 of 188) with videos related to
Page
of 19
Sort By:
Clinical Pharmacology and Therapeutics
|
January 1, 1995
Low CYP1A2 activity in rural Shona children of Zimbabwe
C M Masimirembwa, M Beke, J A Hasler, et al.
Clinical Pharmacology and Therapeutics
|
June 1, 1991
Caffeine as a metabolic probe: validation of its use for acetylator phenotyping
B K Tang, D Kadar, L Qian, et al.
Journal of Chromatography
|
December 9, 1988
High-performance liquid chromatographic analysis of desferrioxamine. Pharmacokinetic and metabolic studies
T P Kruck, K Teichert-Kuliszewska, E Fisher, et al.
Canadian Journal of Physiology and Pharmacology
|
November 1, 1989
Haloperidol reduction can be assayed in human red blood cells
T Inaba, W Kalow, T Someya, et al.
Annals of Internal Medicine
|
August 1, 1986
Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
N H Shear, S P Spielberg, D M Grant, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 1, 1993
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro
D Wu, S V Otton, P Morrow, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 1972
Existence of phospholipid bilayer structure in the inner membrane of mitochondria
J C Hsia, W L Chen, R A Long, et al.
Biochemical and Biophysical Research Communications
|
September 5, 1972
Synthesis of spin labelled 2,4-dinitrophenols and their activities in the uncoupling of oxidative phosphorylation in rat liver mitochondria
J C Hsia, W L Chen, L T Wong, et al.
Clinical Pharmacology and Therapeutics
|
October 23, 1997
Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo
V Ozdemir, C A Naranjo, N Herrmann, et al.
Molecular Pharmacology
|
July 1, 1991
Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6
R F Tyndale, R Sunahara, T Inaba, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 188) with videos related to
Sort By:
Page
of 19
Clinical Pharmacology and Therapeutics
|
January 1, 1995
Low CYP1A2 activity in rural Shona children of Zimbabwe
C M Masimirembwa, M Beke, J A Hasler, et al.
Clinical Pharmacology and Therapeutics
|
June 1, 1991
Caffeine as a metabolic probe: validation of its use for acetylator phenotyping
B K Tang, D Kadar, L Qian, et al.
Journal of Chromatography
|
December 9, 1988
High-performance liquid chromatographic analysis of desferrioxamine. Pharmacokinetic and metabolic studies
T P Kruck, K Teichert-Kuliszewska, E Fisher, et al.
Canadian Journal of Physiology and Pharmacology
|
November 1, 1989
Haloperidol reduction can be assayed in human red blood cells
T Inaba, W Kalow, T Someya, et al.
Annals of Internal Medicine
|
August 1, 1986
Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
N H Shear, S P Spielberg, D M Grant, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 1, 1993
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro
D Wu, S V Otton, P Morrow, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 1972
Existence of phospholipid bilayer structure in the inner membrane of mitochondria
J C Hsia, W L Chen, R A Long, et al.
Biochemical and Biophysical Research Communications
|
September 5, 1972
Synthesis of spin labelled 2,4-dinitrophenols and their activities in the uncoupling of oxidative phosphorylation in rat liver mitochondria
J C Hsia, W L Chen, L T Wong, et al.
Clinical Pharmacology and Therapeutics
|
October 23, 1997
Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo
V Ozdemir, C A Naranjo, N Herrmann, et al.
Molecular Pharmacology
|
July 1, 1991
Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6
R F Tyndale, R Sunahara, T Inaba, et al.
Page
of 19